Retrospective analysis identified biomarkers influencing mortality risk in thrombotic thrombocytopenic purpura patients, suggesting a need for tailored interventions.
Key Points
Elevated cardiac troponin I was linked to a mortality risk increase in patients with thrombotic thrombocytopenic purpura.
Risk stratification scores revealed a progressive increase in mortality risk, from 21.3% to 92.3% across scoring thresholds.
Receiver operating characteristic analysis was employed to establish cutoffs for laboratory biomarkers determining mortality risk.
Both internal and external validations confirmed the effectiveness of the predictive model for short-term mortality.